{"id":"c4a99eae-197c-4f81-87d5-e5d90da22117","question":"What medical conditions or situations would make it unsafe to use chlordiazepoxide hydrochloride and clidinium bromide capsules?","reference_answer":"Chlordiazepoxide hydrochloride and clidinium bromide capsules are contraindicated in the presence of glaucoma, in patients with prostatic hypertrophy and benign bladder neck obstruction, and in patients with known hypersensitivity to chlordiazepoxide hydrochloride and\/or clidinium bromide.","reference_context":"Document 2: the maximum recommended human dose of 40 mg\/day, based on body surface area)\nexhibited major skeletal defects.\nTwo series of reproduction experiments with clidinium bromide were carried out in rats,\nemploying dosages of 2.5 and 10 mg\/kg daily (1.2 and 4.9 times, respectively, the\nmaximum recommended clinical dose of 20 mg\/day, based on body surface area) in\neach experiment. In the first experiment, clidinium bromide was administered for a 9-\nweek interval prior to mating; no untoward effect on fertilization or gestation was noted.\nThe offspring were taken by caesarean section and did not show a significant incidence\nof congenital anomalies when compared to control animals. In the second experiment,\nadult animals were given clidinium bromide for 10 days prior to and through two mating\ncycles. No significant effects were observed on fertility, gestation, viability of offspring or\nlactation, as compared to control animals, nor was there a significant incidence of\ncongenital anomalies in the offspring derived from these experiments.\nA reproduction study was carried out in rats through two successive matings with\nadministration of oral daily doses of 2.5 mg\/kg chlordiazepoxide hydrochloride and 1.25\nmg\/kg clidinium bromide (0.6 times the maximum recommended clinical dose for both\ndrugs, based on body surface area) or 25 mg\/kg chlordiazepoxide hydrochloride and\n12.5 mg\/kg clidinium bromide (6.1 times the maximum recommended clinical dose for\nboth drugs, based on body surface area). In the first mating, no significant differences\nwere noted between the control or the treated groups, with the exception of a slight\ndecrease in the number of animals surviving during lactation among those receiving the\nhigh dosage. In the second mating, similar results were obtained except for a slight\ndecrease in the number of pregnant females and in the percentage of offspring\nsurviving until weaning. No congenital anomalies were observed in both matings in either\nthe control or treated groups.\n   \nINDICATIONS \nAND USAGE\nChlordiazepoxide hydrochloride and clidinium bromide capsules are indicated to control\nemotional and somatic factors in gastrointestinal disorders. Chlordiazepoxide\nhydrochloride and clidinium bromide capsules may also be used as adjunctive therapy in\nthe treatment of peptic ulcer and in the treatment of the irritable bowel syndrome\n(irritable colon, spastic colon, mucous colitis) and acute enterocolitis.\nCONTRAINDICATIONS\nChlordiazepoxide hydrochloride and clidinium bromide capsules are contraindicated in\nthe presence of glaucoma (since the anticholinergic component may produce some\ndegree of mydriasis) and in patients with prostatic hypertrophy and benign bladder neck\nobstruction. It is contraindicated in patients with known hypersensitivity to\nchlordiazepoxide hydrochloride and\/or clidinium bromide.\nWARNINGS","conversation_history":[],"metadata":{"question_type":"complex","seed_document_id":2,"topic":"Pregnancy and Medication"}}
{"id":"d5547a7d-6639-478b-a3ad-e4cbb5b9b7b0","question":"What is the specific color of the capsule for the product with NDC code 62332-744-31 according to the provided document?","reference_answer":"The color of the capsule for the product with NDC code 62332-744-31 is light green, with a light green opaque cap and body.","reference_context":"Document 19: Alembic Pharmaceuticals Inc.\nPOTASSIUM HYDROXIDE\n (UNII: WZH3C48M4T)\n \nPROPYLENE GLYCOL\n (UNII: 6DC9Q167V3)\n \nProduct Characteristics\nColor\nGREEN (Light green opaque cap) , GREEN (Light green opaque body)\nScore\nno score\nShape\nCAPSULE\nSize\n16mm\nFlavor\nImprint Code\nA;333\nContains\n    \nPackaging\n#\nItem Code\nPackage Description\nMarketing Start\nDate\nMarketing End\nDate\n1\nNDC:62332-744-\n31\n100 \nin 1 BOTTLE; Type 0: Not a Combination\nProduct\n10\/04\/2023\n2\nNDC:62332-744-\n91\n1000 \nin 1 BOTTLE; Type 0: Not a Combination\nProduct\n10\/04\/2023\nMarketing Information\nMarketing\nCategory\nApplication Number or Monograph\nCitation\nMarketing Start\nDate\nMarketing End\nDate\nANDA\nANDA216969\n10\/04\/2023\nLabeler - \nAlembic Pharmaceuticals Inc. \n(079288842)\nEstablishment\nName\nAddress\nID\/FEI\nBusiness Operations\nAlembic Pharmaceuticals Limited\n650574671\nMANUFACTURE(62332-744)\n \nRevised: 10\/2023","conversation_history":[],"metadata":{"question_type":"complex","seed_document_id":19,"topic":"Lice Treatment"}}
{"id":"0e7a51d5-3c85-4398-a20f-4ec8dcd67560","question":"What specific drug is referenced in the provided context?","reference_answer":"Ivermectin","reference_context":"Document 26: IVERMECTIN","conversation_history":[],"metadata":{"question_type":"complex","seed_document_id":26,"topic":"Others"}}
{"id":"15f1f97d-d891-470d-b74a-91fedbab2230","question":"What are the potential withdrawal symptoms that can occur as a result of abrupt discontinuation or rapid dosage reduction of benzodiazepines, and how long can these withdrawal symptoms persist in some cases?","reference_answer":"Withdrawal symptoms of benzodiazepine use can include acute withdrawal reactions such as seizures, protracted withdrawal syndrome lasting weeks to over 12 months, and neonatal sedation and withdrawal syndrome in babies born to mothers who used benzodiazepines late in pregnancy.","reference_context":"Document 4: those who have had longer durations of use.\nAcute Withdrawal Reactions\nThe continued use of benzodiazepines, including chlordiazepoxide hydrochloride and\nclidinium bromide capsules, may lead to clinically significant physical dependence. Abrupt\ndiscontinuation or rapid dosage reduction of chlordiazepoxide hydrochloride and\nclidinium bromide capsules after continued use, or administration of flumazenil (a\nbenzodiazepine antagonist) may precipitate acute withdrawal reactions, which can be\nlife-threatening (e.g., seizures) (see \nDRUG ABUSE AND DEPENDENCE\n)\n.\nProtracted Withdrawal Syndrome\nIn some cases, benzodiazepine users have developed a protracted withdrawal\nsyndrome with withdrawal symptoms lasting weeks to more than 12 months (see \nDRUG\nABUSE AND DEPENDENCE\n).\nEffects on the Ability to Drive or Operate Machinery\nAs in the case of other preparations containing CNS-acting drugs, patients receiving\nchlordiazepoxide hydrochloride and clidinium bromide capsules should be cautioned\nabout possible combined effects with opioids, alcohol and other CNS depressants. For\nthe same reason, they should be cautioned against hazardous occupations requiring\ncomplete mental alertness, such as operating machinery or driving a motor vehicle.\nNeonatal Sedation and Withdrawal Syndrome\nUse of benzodiazepines late in pregnancy can result in sedation (respiratory depression,\nlethargy, hypotonia) and\/or withdrawal symptoms (hyperreflexia, irritability,\nrestlessness, tremors, inconsolable crying, and feeding difficulties) in the neonate (see\nPRECAUTIONS, Pregnancy\n). Monitor neonates exposed to chlordiazepoxide\nhydrochloride and clidinium bromide capsules, which contains a benzodiazepine\n(chlordiazepoxide hydrochloride), during pregnancy and labor for signs of sedation and\nmonitor neonates exposed to chlordiazepoxide hydrochloride and clidinium bromide\ncapsules during pregnancy for signs of withdrawal; manage these neonates accordingly.\n  \nPRECAUTIONS\nCNS Adverse Reactions\nIn geriatric or debilitated patients, it is recommended that the dosage be limited to the\nsmallest effective amount to preclude the development of ataxia, oversedation or\nconfusion (not more than 2 chlordiazepoxide hydrochloride and clidinium bromide\ncapsules per day initially, to be increased gradually as needed and tolerated). In general,\nthe concomitant administration of chlordiazepoxide hydrochloride and clidinium bromide\ncapsules and other psychotropic agents is not recommended. If such combination\ntherapy seems indicated, careful consideration should be given to the pharmacology of\nthe agents to be employed — particularly when the known potentiating compounds such","conversation_history":[],"metadata":{"question_type":"complex","seed_document_id":4,"topic":"Pregnancy and Medication"}}
{"id":"606932e4-9e75-41d5-9333-ea484f39255d","question":"What is the weight of the tube in grams according to document 23?","reference_answer":"The net weight of the tube is 4 ounces (117 grams).","reference_context":"Document 23: 1\nTUBE\nNET WT 4 OZ (117 g)","conversation_history":[],"metadata":{"question_type":"complex","seed_document_id":23,"topic":"Lice Treatment"}}
{"id":"699086f9-ace2-4245-af92-746ce1f5667d","question":"What are the potential fetal\/neonatal adverse reactions that may arise as a result of benzodiazepines crossing the placenta, particularly in neonates exposed to chlordiazepoxide hydrochloride and clidinium bromide capsules during pregnancy or labor?","reference_answer":"Benzodiazepines crossing the placenta may produce respiratory depression, hypotonia, and sedation in neonates. Neonates exposed to chlordiazepoxide hydrochloride and clidinium bromide capsules during pregnancy or labor should be monitored for signs of sedation, respiratory depression, hypotonia, and feeding problems.","reference_context":"Document 7: defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to\n20%, respectively.\nClinical Considerations\nFetal\/Neonatal Adverse Reactions\nBenzodiazepines cross the placenta and may produce respiratory depression, hypotonia\nand sedation in neonates. Monitor neonates exposed to chlordiazepoxide hydrochloride\nand clidinium bromide capsules, which contains a benzodiazepine (chlordiazepoxide\nhydrochloride), during pregnancy or labor for signs of sedation, respiratory depression,\nhypotonia, and feeding problems. Monitor neonates exposed to chlordiazepoxide\nhydrochloride and clidinium bromide capsules during pregnancy for signs of withdrawal.\nManage these neonates accordingly (see \nWARNINGS, Neonatal Sedation and\nWithdrawal Syndrome\n).\nData\nHuman Data\nPublished data from observational studies on the use of benzodiazepines during\npregnancy do not report a clear association with benzodiazepines and major birth\ndefects. Although early studies reported an increased risk of congenital malformations\nwith diazepam and chlordiazepoxide, there was no consistent pattern noted. In addition,\nthe majority of more recent case-control and cohort studies of benzodiazepine use\nduring pregnancy, which were adjusted for confounding exposures to alcohol. Tobacco\nand other medications, have not confirmed these findings.\nAnimal Data\nOral daily doses of 2.5 mg\/kg chlordiazepoxide hydrochloride with 1.25 mg\/kg clidinium\nbromide or 25 mg\/kg chlordiazepoxide hydrochloride with 12.5 mg\/kg clidinium bromide\n(0.6 and 6.1 times, respectively, the maximum recommended clinical dose for both\ndrugs, based on body surface area) were administered to rats in a reproduction study\nthrough two successive matings. In the first mating, no significant differences were\nnoted between the control or the treated groups, with the exception of a slight decrease\nin the number of animals surviving during lactation among those receiving the highest\ndosage. In the second mating, similar results were obtained except for a slight decrease\nin the number of pregnant females and in the percentage of offspring surviving until\nweaning. No congenital anomalies were observed in both matings in either the control or\ntreated groups.\nNursing Mothers\nChlordiazepoxide Hydrochloride\nThere are no data on the presence of chlordiazepoxide in either human or animal milk,\nthe effects on the breastfed infant, or the effects on milk production. However, there\nare reports of sedation, poor feeding and poor weight gain in infants exposed to other\nbenzodiazepines through breast milk.","conversation_history":[],"metadata":{"question_type":"complex","seed_document_id":7,"topic":"Pregnancy and Medication"}}
{"id":"af8510fd-54e2-4edc-b564-e1d6b5d61274","question":"What severe consequences may arise from the simultaneous use of benzodiazepines and opioids, and what precautions should be taken to mitigate these risks?","reference_answer":"The risks associated with the concomitant use of benzodiazepines and opioids include profound sedation, respiratory depression, coma, and death. It is advised to reserve concomitant prescribing of these drugs for patients when alternative treatment options are inadequate, limit dosages and durations to the minimum required, and closely monitor patients for signs of respiratory depression and sedation.","reference_context":"Document 0: CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE -\nchlordiazepoxide hydrochloride and clidinium bromide capsule \n \nAlembic Pharmaceuticals Inc.\n----------\nChlordiazepoxide Hydrochloride and Clidinium Bromide Capsules, USP\nfor oral use\nWARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE,\nMISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL\nREACTIONS\n \nConcomitant use of benzodiazepines and opioids may result in\nprofound sedation, respiratory depression, coma, and death. Reserve\nconcomitant prescribing of these drugs in patients for whom\nalternative treatment options are inadequate. Limit dosages and\ndurations to the minimum required. Follow patients for signs and\nsymptoms of respiratory depression and sedation (see WARNINGS\nand PRECAUTIONS and PRECAUTIONS, Drug Interactions).\n \nThe use of benzodiazepines, including chlordiazepoxide hydrochloride,\na component of chlordiazepoxide hydrochloride and clidinium bromide\ncapsules, exposes users to risks of abuse, misuse, and addiction,\nwhich can lead to overdose or death. Abuse and misuse of\nbenzodiazepines commonly involve concomitant use of other\nmedications, alcohol, and\/or illicit substances, which is associated\nwith an increased frequency of serious adverse outcomes. Before\nprescribing chlordiazepoxide hydrochloride and clidinium bromide\ncapsules and throughout treatment, assess each patient’s risk for\nabuse, misuse, and addiction (see WARNINGS)\n.\n \nThe continued use of benzodiazepines, including chlordiazepoxide\nhydrochloride and clidinium bromide capsules, may lead to clinically\nsignificant physical dependence. The risks of dependence and\nwithdrawal increase with longer treatment duration and higher daily\ndose. Abrupt discontinuation or rapid dosage reduction of\nchlordiazepoxide hydrochloride and clidinium bromide capsules after\ncontinued use may precipitate acute withdrawal reactions, which can\nbe life-threatening. To reduce the risk of withdrawal reactions, use a\ngradual taper to discontinue chlordiazepoxide hydrochloride and\nclidinium bromide capsules or reduce the dosage \n(see WARNINGS and\nDOSAGE AND ADMINISTRATION).\nDESCRIPTION\nChlordiazepoxide hydrochloride and clidinium bromide capsules, USP are a fixed-\ncombination of chlordiazepoxide hydrochloride, a benzodiazepine, and clidinium\nbromide, an anticholinergic.","conversation_history":[],"metadata":{"question_type":"complex","seed_document_id":0,"topic":"Pregnancy and Medication"}}
{"id":"66dc0d38-b4a5-4ed7-969b-044270307079","question":"What are the active ingredients present in chlordiazepoxide hydrochloride and clidinium bromide capsules according to the provided health professional document?","reference_answer":"The active ingredients in chlordiazepoxide hydrochloride and clidinium bromide capsules are chlordiazepoxide hydrochloride and clidinium bromide.","reference_context":"Document 17: that is written for health professionals.\nWhat are the ingredients in chlordiazepoxide hydrochloride and clidinium\nbromide capsules? \nActive ingredients:\n chlordiazepoxide hydrochloride and clidinium bromide \nInactive ingredients: \nlactose monohydrate, corn starch, talc, titanium dioxide, FD&C\nGreen 3, D&C Yellow 10 and gelatin. The empty hard gelatin capsule shells are printed\nwith edible black ink containing shellac, propylene glycol,  iron oxide and black iron oxide\nand potassium hydroxide. \n \nMedication Guide available at \nhttps:\/\/www.alembicusa.com\/medicationguide.aspx\n or call\n1-866-210-9797.\n \nManufactured by: \nAlembic Pharmaceuticals Limited\n \n(Formulation Division),\nPanelav 389350, Gujarat, India\n \nManufactured for:\nAlembic Pharmaceuticals Limited\n \nBedminster, NJ 07921, USA\nFor more information, contact Alembic Pharmaceuticals Limited at 1-866-210-9797.\nThis Medication Guide has been approved by the U.S. Food and Drug\nAdministration.              Revised: 02\/2023\nPACKAGE LABEL.PRINCIPAL DISPLAY PANEL\nNDC 62332-744-31\nChlordiazepoxide\nHydrochloride and Clidinium\nBromide Capsules, USP\n5 mg\/2.5 mg\nPHARMACIST: DISPENSE THE ACCOMPANYING\nMEDICATION GUIDE TO EACH PATIENT.\nRx only\n100 Capsules\nAlembic","conversation_history":[],"metadata":{"question_type":"complex","seed_document_id":17,"topic":"Others"}}
{"id":"87fa7df6-5ca3-4c80-8fde-582eb17abedc","question":"What are the names and strengths of the active ingredients found in the tablet identified by the item code NDC:73097-009?","reference_answer":"The active ingredients in the tablet with item code NDC:73097-009 are Acetaminophen (325 mg), Dextromethorphan Hydrobromide (10 mg), Doxylamine Succinate (6.25 mg), and Phenylephrine Hydrochloride (5 mg).","reference_context":"Document 32: acetaminophen, dextromethorphan hydrobromide, doxylamine succinate, phenylephrine hydrochloride tablet, coated\nProduct Information\nProduct Type\nHUMAN OTC DRUG\nItem Code (Source)\nNDC:73097-009(NDC:37000-813)\nRoute of Administration\nORAL\nActive Ingredient\/Active Moiety\nIngredient Name\nBasis of Strength\nStrength\nACETAMINOPHEN\n (UNII: 362O9ITL9D) \n(ACETAMINOPHEN - UNII:362O9ITL9D)\nACETAMINOPHEN\n325 mg\nDEXTROMETHORPHAN HYDROBROMIDE\n (UNII: 9D2RTI9KYH)\n(DEXTROMETHORPHAN - UNII:7355X3ROTS)\nDEXTROMETHORPHAN\nHYDROBROMIDE\n10 mg\nDOXYLAMINE SUCCINATE\n (UNII: V9BI9B5YI2) \n(DOXYLAMINE - UNII:95QB77JKPL)\nDOXYLAMINE SUCCINATE\n6.25 mg\nPHENYLEPHRINE HYDROCHLORIDE\n (UNII: 04JA59TNSJ) \n(PHENYLEPHRINE -\nUNII:1WS297W6MV)\nPHENYLEPHRINE\nHYDROCHLORIDE\n5 mg\nInactive Ingredients\nIngredient Name\nStrength\nFD&C BLUE NO. 2\n (UNII: L06K8R7DQK)\n \nCROSPOVIDONE\n (UNII: 68401960MK)\n \nFD&C YELLOW NO. 6\n (UNII: H77VEI93A8)\n \nFD&C BLUE NO. 1\n (UNII: H3R47K3TBD)\n \nD&C YELLOW NO. 10\n (UNII: 35SW5USQ3G)\n \nMAGNESIUM STEARATE\n (UNII: 70097M6I30)\n \nSILICON DIOXIDE\n (UNII: ETJ7Z6XBU4)\n \nCELLULOSE, MICROCRYSTALLINE\n (UNII: OP1R32D61U)\n \nPOLYETHYLENE GLYCOL, UNSPECIFIED\n (UNII: 3WJQ0SDW1A)\n \nPOLYVINYL ALCOHOL\n (UNII: 532B59J990)\n \nPOVIDONE\n (UNII: FZ989GH94E)\n \nSTEARIC ACID\n (UNII: 4ELV7Z65AP)\n \nTALC\n (UNII: 7SEV7J4R1U)\n \nTITANIUM DIOXIDE\n (UNII: 15FIX9V2JP)\n \nProduct Characteristics\nColor\ngreen\nScore\nno score\nShape\nOVAL\nSize\n1mm\nFlavor\nImprint Code\nNQ\nContains\n    \nPackaging\n#\nItem Code\nPackage Description\nMarketing Start Date\nMarketing End Date\n1\nNDC:73097-009-25\n50 \nin 1 CARTON\n07\/08\/2019\n1\n2 \nin 1 POUCH; Type 0: Not a Combination Product\n2\nNDC:73097-009-02\n1 \nin 1 CARTON\n07\/08\/2019\n2\n2 \nin 1 POUCH; Type 0: Not a Combination Product","conversation_history":[],"metadata":{"question_type":"complex","seed_document_id":32,"topic":"Lice Treatment"}}
{"id":"c498ad2d-c9cb-49bc-8fac-c54013942521","question":"What are the potential dangers associated with the consumption of chlordiazepoxide hydrochloride and clidinium bromide capsules when combined with opioid medications, alcohol, or other central nervous system depressants?","reference_answer":"Taking chlordiazepoxide hydrochloride and clidinium bromide capsules with opioid medicines, alcohol, or other central nervous system depressants can cause severe drowsiness, breathing problems, coma, and death. There is also a risk of abuse, misuse, and addiction with benzodiazepines, including this medication.","reference_context":"Document 13: on cap and “333” on body with black ink, filled with white to off white powder.\nBottle of 100 capsules with child resistant closure, NDC 62332-744-31\nBottle of 1000 capsules, NDC 62332-744-91\nStore at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP\nControlled Room Temperature]. Protect from light.\nKeep out of reach of children.\nDispense in tight, light-resistant container as defined in USP\/NF.\nMedication Guide available at \nhttps:\/\/www.alembicusa.com\/medicationguide.aspx \nor call\n1-866-210-9797.\nManufactured by: \nAlembic Pharmaceuticals Limited\n \n(Formulation Division),\nPanelav 389350, Gujarat, India\nManufactured for:\nAlembic Pharmaceuticals Limited\n \nBedminster, NJ 07921, USA\nRevised: 02\/2023\nMEDICATION GUIDE\nChlordiazepoxide Hydrochloride (klor” dye az” e pox’ ide hye” droe klor’ ide)\nand\nClidinium Bromide (kli din’ ee um broe’ mide) \nCapsules, USP\nfor oral use \n \nWhat is the most important information I should know about\nchlordiazepoxide hydrochloride and clidinium bromide capsules?\n \n• Chlordiazepoxide hydrochloride and clidinium bromide capsule contains a\nbenzodiazepine medicine. Taking chlordiazepoxide hydrochloride and clidinium\nbromide capsules with opioid medicines, alcohol, or other central nervous\nsystem (CNS) depressants (including street drugs) can cause severe\ndrowsiness, breathing problems (respiratory depression), coma, and death. \n \nGet emergency help right away if any of the following happens: \n      o shallow or slowed breathing \n      o breathing stops (which may lead to the heart stopping) \n      o excessive sleepiness (sedation) \nDo not drive or operate heavy machinery until you know how taking chlordiazepoxide\nhydrochloride and clidinium bromide capsules with opioids affects you. \n• Risk of abuse, misuse, and addiction. \nThere is a risk of abuse, misuse, and\naddiction with benzodiazepines, including chlordiazepoxide hydrochloride and clidinium","conversation_history":[],"metadata":{"question_type":"complex","seed_document_id":13,"topic":"Pregnancy and Medication"}}
{"id":"5eeddd22-3a6d-454a-8d49-fd7191b391c6","question":"What factors should be taken into consideration when determining the maintenance dose for chlordiazepoxide hydrochloride and clidinium bromide capsules, and what is the usual recommended maintenance dose regimen for this medication?","reference_answer":"The usual maintenance dose is 1 or 2 capsules, 3 or 4 times a day administered before meals and at bedtime.","reference_context":"Document 12: overdosage. Anticholinergic drugs usually increase heart rate and blood pressure. In\nmanaging benzodiazepine overdosage, employ general supportive measures, including\nintravenous fluids, and airway management.\nFlumazenil, a specific benzodiazepine receptor antagonist is indicated for the complete\nor partial reversal of the sedative effects of benzodiazepines in the management of\nbenzodiazepine overdosage. Use of flumazenil may increase the risk of seizures in\nmixed overdosage with drugs that may precipitate seizures, including anticholinergic\nmedications. Benzodiazepines are used to treat agitated delirium from anticholinergic\ntoxicity. Therefore flumazenil administration may worsen the anticholinergic delirium and\nshould generally be avoided.\nAnticholinesterase inhibitors may reverse severe agitated delirium that is not controlled\nby benzodiazepines. They may also improve the airway and breathing in CNS depressed\npatients. Caution is warranted especially in mixed drug overdoses.\nConsider contacting a poison center (1-800-222-1222) or a medical toxicologist for\noverdosage management recommendations.\nDOSAGE \nAND ADMINISTRATION\nRecommended Dosage\nBecause of the varied individual responses to tranquilizers and anticholinergics, the\noptimum dosage of chlordiazepoxide hydrochloride and clidinium bromide capsules\nvaries with the diagnosis and response of the individual patient. The dosage, therefore,\nshould be individualized for maximum beneficial effects. The usual maintenance dose is 1\nor 2 capsules, 3 or 4 times a day administered before meals and at bedtime.\n \nRecommended Geriatric Dosage\nDosage should be limited to the smallest effective amount to preclude the development\nof ataxia, oversedation or confusion. The initial dose should not exceed 2\nchlordiazepoxide hydrochloride and clidinium bromide capsules per day, to be increased\ngradually as needed and tolerated. Elderly patients have an increased risk of dose-\nrelated adverse reactions (see \nPRECAUTIONS\n).\nDiscontinuation or Dosage Reduction of \nChlordiazepoxide Hydrochloride and\nClidinium Bromide Capsules\nTo reduce the risk of withdrawal reactions, use a gradual taper to discontinue\nchlordiazepoxide hydrochloride and clidinium bromide capsules or reduce the dosage. If\na patient develops withdrawal reactions, consider pausing the taper or increasing the\ndosage to the previous tapered dosage level. Subsequently decrease the dosage more\nslowly (see \nWARNINGS \nand \nDRUG ABUSE AND DEPENDENCE\n).\nHOW SUPPLIED\nChlordiazepoxide hydrochloride and clidinium bromide capsules, USP are opaque light\ngreen cap\/opaque light green body hard gelatin capsule, size “3” having imprinting “A”","conversation_history":[],"metadata":{"question_type":"complex","seed_document_id":12,"topic":"Pregnancy and Medication"}}
{"id":"1aadfdb9-d14e-4699-bb27-cef597a1241e","question":"What specific skin condition is Ivermectin lotion primarily used to treat, and what are the restrictions for its application?","reference_answer":"The purpose of Ivermectin lotion is to treat head lice.","reference_context":"Document 20: IVERMECTIN- ivermectin lotion \n \nWalgreen Company\n----------\nIvermectin\nDrug Facts\nActive ingredient\nIvermectin 0.5%\nPurpose\nLice treatment\nUse\ntreats head lice\nWarnings\nFor external use only. Use only on the scalp.\nDo not use\non children under 6 months of age\nnear the eyes\ninside the nose, ear, mouth, or vagina\non lice in eyebrows or eyelashes. See a doctor if lice are present in these areas.\nAsk a doctor before use if you\nhave any skin conditions or sensitivities\nare pregnant or plan to become pregnant. It is not known if product can harm your\nunborn baby.\nare currently or planning to breastfeed. Avoid getting product on your breast to help\nprevent contact by your baby.\nWhen using this product\nkeep eyes tightly closed and protect eyes with a washcloth or towel\nif product gets into eyes, gently flush with water\neye redness, soreness, or irritation can occur\ndandruff, dry skin, or burning sensation of the skin can occur\nStop use and ask a doctor if\nbreathing difficulty occurs\neye irritation occurs\nskin or scalp irritation continues or infection occurs\nrash develops","conversation_history":[],"metadata":{"question_type":"complex","seed_document_id":20,"topic":"Lice Treatment"}}
{"id":"fbe05ff6-c229-41e0-91c5-3a84c039d10b","question":"What are the active ingredients present in each chlordiazepoxide hydrochloride and clidinium bromide capsule, USP, and can you list them individually?","reference_answer":"Each capsule contains 5 mg of chlordiazepoxide hydrochloride, USP and 2.5 mg of clidinium bromide, USP.","reference_context":"Document 1: Each chlordiazepoxide hydrochloride and clidinium bromide capsule, USP contains the\nactive ingredients 5 mg chlordiazepoxide hydrochloride, USP and 2.5 mg clidinium\nbromide, USP. Each capsule also contains the inactive ingredients lactose monohydrate,\ncorn starch, talc, titanium dioxide, FD&C Green 3, D&C Yellow 10 and gelatin. The empty\nhard gelatin capsule shells are printed with edible black ink containing shellac, propylene\nglycol,  black iron oxide and potassium hydroxide.\nChlordiazepoxide hydrochloride, USP is 7-chloro-2-methylamino-5-phenyl-3H-1,4-\nbenzodiazepine 4-oxide hydrochloride. A white or practically white crystalline powder, it\nis soluble in water, sparingly soluble in alcohol and insoluble in solvent hexane. It is\nunstable in solution and the powder must be protected from light. The molecular weight\nis 336.22. The structural formula of chlordiazepoxide hydrochloride, USP is as follows:\nClidinium bromide, USP is a synthetic anticholinergic agent which has been shown in\nexperimental and clinical studies to have antispasmodic and antisecretory effects on the\ngastrointestinal tract.\nStructurally clidinium bromide, USP is:\n   \nProduct meets USP Dissolution Test 2.\nANIMAL PHARMACOLOGY AND\/OR ANIMAL TOXICOLOGY\n  \nEffects on Reproduction\nReproduction studies in rats fed chlordiazepoxide hydrochloride, 10, 20 and 80 mg\/kg\ndaily (2.4, 4.8 and 19.4 times, respectively, the maximum recommended clinical dose of\n40 mg\/day, based on body surface area), and bred through one or two matings showed\nno congenital anomalies, nor were there adverse effects on growth of the newborn.\nHowever, in another study at 100 mg\/kg daily there was noted a significant decrease in\nthe fertilization rate and a marked decrease in the viability and body weight of offspring\nwhich may be attributable to sedative activity, thus resulting in lack of interest in mating\nand lessened maternal nursing and care of the young. One neonate in each of the first\nand second matings in the rat reproduction study at the 100 mg\/kg dose (24.2 times","conversation_history":[],"metadata":{"question_type":"complex","seed_document_id":1,"topic":"Pregnancy and Medication"}}
{"id":"cef48986-f289-41a8-b4fb-315710fb6703","question":"What are the medical conditions for which chlordiazepoxide hydrochloride and clidinium bromide capsule is prescribed, and what precautions should be taken to prevent misuse and abuse of this medication?","reference_answer":"Chlordiazepoxide hydrochloride and clidinium bromide capsule is a prescription medicine used in conjunction with other therapies for the treatment of stomach (peptic) ulcers, irritable bowel syndrome (IBS), and inflammation of the colon known as acute enterocolitis.","reference_context":"Document 14: bromide capsules, which can lead to overdose or death. \n        o \nSerious side effects including coma and death have happened in people\nwho have abused or misused benzodiazepines, including chlordiazepoxide\nhydrochloride and clidinium bromide capsules. \nThese serious side effects may also\ninclude delirium, paranoia, suicidal thoughts or actions, seizures, and difficulty breathing.\nCall your healthcare provider or go to the nearest hospital emergency room\nright away if you get any of these serious side effects.\n \n        o \nYou can develop an addiction even if you take chlordiazepoxide\nhydrochloride and clidinium bromide capsules as prescribed by your\nhealthcare provider. \n       o \nTake chlordiazepoxide hydrochloride and clidinium bromide capsules\nexactly as your healthcare provider prescribed.\n \n      o Do not share your chlordiazepoxide hydrochloride and clidinium bromide capsules\nwith other people. \n      o Keep chlordiazepoxide hydrochloride and clidinium bromide capsules in a safe\nplace and away from children. \n• Physical dependence and withdrawal reactions. \nChlordiazepoxide hydrochloride\nand clidinium bromide capsules can cause physical dependence and withdrawal\nreactions. \n     o \nDo not suddenly stop using chlordiazepoxide hydrochloride and clidinium\nbromide capsules.\n Stopping chlordiazepoxide hydrochloride and clidinium bromide\ncapsules suddenly can cause serious and life-threatening side effects, including unusual\nmovements, responses, or expressions, seizures, sudden and severe mental or\nnervous system changes, depression, seeing or hearing things that others do not see\nor hear, an extreme increase in activity or talking, losing touch with reality, and suicidal\nthoughts or actions.\n Call your healthcare provider or go to the nearest hospital\nemergency room right away if you get any of these symptoms. \n      o \nSome people who suddenly stop benzodiazepines have symptoms that\ncan last for several weeks to more than 12 months, \nincluding anxiety, trouble\nremembering, learning, or concentrating, depression, problems sleeping, feeling like\ninsects are crawling under your skin, weakness, shaking, muscle twitches, burning or\nprickling feeling in your hands, arms, legs or feet, and ringing in your ears. \n      o Physical dependence is not the same as drug addiction. Your healthcare provider\ncan tell you more about the differences between physical dependence and drug\naddiction.\n     o Do not take more chlordiazepoxide hydrochloride and clidinium bromide capsules\nthan prescribed or take chlordiazepoxide hydrochloride and clidinium bromide capsules\nfor longer than prescribed. \n \nWhat is chlordiazepoxide hydrochloride and clidinium bromide capsule? \n• Chlordiazepoxide hydrochloride and clidinium bromide capsule is a prescription\nmedicine that is used with other therapies for the treatment of: \n       o stomach (peptic) ulcers \n       o irritable bowel syndrome (IBS) \n      o inflammation of the colon called acute enterocolitis \n• Chlordiazepoxide hydrochloride and clidinium bromide capsule contains the medicines\nchlordiazepoxide hydrochloride and clidinium bromide. \n• Chlordiazepoxide hydrochloride and clidinium bromide capsule contains\nchlordiazepoxide hydrochloride that can be abused or lead to dependence.\nKeep chlordiazepoxide hydrochloride and clidinium bromide capsules in a safe place to\nprevent misuse and abuse. Selling or giving away chlordiazepoxide hydrochloride and","conversation_history":[],"metadata":{"question_type":"complex","seed_document_id":14,"topic":"Pregnancy and Medication"}}
{"id":"3f13730e-ab9a-43f4-86d0-1266c4ed76ad","question":"What are some of the severe adverse reactions that have been reported specifically with benzodiazepine abuse and\/or misuse, and what factors are often associated with an increased risk of these reactions?","reference_answer":"Some severe adverse reactions that have occurred with benzodiazepine abuse and\/or misuse include delirium, paranoia, suicidal ideation and behavior, seizures, coma, breathing difficulty, and death. Death is more often associated with polysubstance use, especially combining benzodiazepines with other CNS depressants such as opioids and alcohol.","reference_context":"Document 10: Abuse and misuse of benzodiazepines often (but not always) involve the use of doses\ngreater than the maximum recommended dosage and commonly involve concomitant\nuse of other medications, alcohol, and\/or illicit substances, which is associated with an\nincreased frequency of serious adverse outcomes, including respiratory depression,\noverdose, or death. Benzodiazepines are often sought by individuals who abuse drugs\nand other substances, and by individuals with addictive disorders (see \nWARNINGS\n).\nThe following adverse reactions have occurred with benzodiazepine abuse and\/or\nmisuse: abdominal pain, amnesia, anorexia, anxiety, aggression, ataxia, blurred vision,\nconfusion, depression, disinhibition, disorientation, dizziness, euphoria, impaired\nconcentration and memory, indigestion, irritability, muscle pain, slurred speech, tremors,\nand vertigo.\nThe following severe adverse reactions have occurred with benzodiazepine abuse and\/or\nmisuse: delirium, paranoia, suicidal ideation and behavior, seizures, coma, breathing\ndifficulty, and death. Death is more often associated with polysubstance use (especially\nbenzodiazepines with other CNS depressants such as opioids and alcohol).\nDependence\nPhysical Dependence\n \nChlordiazepoxide hydrochloride and clidinium bromide capsules may produce physical\ndependence from continued therapy. Physical dependence is a state that develops as a\nresult of physiological adaptation in response to repeated drug use, manifested by\nwithdrawal signs and symptoms after abrupt discontinuation or a significant dose\nreduction of a drug. Abrupt discontinuation or rapid dosage reduction of\nbenzodiazepines or administration of flumazenil, a benzodiazepine antagonist, may\nprecipitate acute withdrawal reactions, including seizures, which can be life-threatening.\nPatients at an increased risk of withdrawal adverse reactions after benzodiazepine\ndiscontinuation or rapid dosage reduction include those who take higher dosages (i.e.,\nhigher and\/or more frequent doses) and those who have had longer durations of use\n(see \nWARNINGS\n).\nTo reduce the risk of withdrawal reactions, use a gradual taper to discontinue\nchlordiazepoxide hydrochloride and clidinium bromide capsules or reduce the dosage\n(see \nWARNINGS \nand \nDOSAGE AND ADMININSTRATION\n).\n \n \nAcute Withdrawal Signs and Symptoms\n \nAcute withdrawal signs and symptoms associated with benzodiazepines have included\nabnormal involuntary movements, anxiety, blurred vision, depersonalization, depression,\nderealization, dizziness, fatigue, gastrointestinal adverse reactions (e.g., nausea,\nvomiting, diarrhea, weight loss, decreased appetite), headache, hyperacusis,\nhypertension, irritability, insomnia, memory impairment, muscle pain and stiffness, panic\nattacks, photophobia, restlessness, tachycardia, and tremor. More severe acute\nwithdrawal signs and symptoms, including life-threatening reactions, have included\ncatatonia, convulsions, delirium tremens, depression, hallucinations, mania, psychosis,","conversation_history":[],"metadata":{"question_type":"complex","seed_document_id":10,"topic":"Pregnancy and Medication"}}
{"id":"592538a7-39cc-4d91-bd8f-fd747bfff0dd","question":"What are the specific active ingredients present in NyQuil Severe Cold & Flu caplets and what are their respective purposes according to the drug facts provided?","reference_answer":"The active ingredients in each NyQuil Severe Cold & Flu caplet are Acetaminophen (325 mg), Dextromethorphan HBr (10 mg), Doxylamine succinate (6.25 mg), and Phenylephrine HCL (5 mg).","reference_context":"Document 29: NYQUIL SEVERE COLD AND FLU- acetaminophen, dextromethorphan hydrobromide,\ndoxylamine succinate, phenylephrine hydrochloride tablet, coated \n \nSavings Distributors LLC\nDisclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they\ncomply with applicable regulations and policies. FDA has not evaluated whether this product complies.\n----------\nNyQuil Severe Cold & Flu\nDrug Facts\nActive ingredients (in each caplet)\nAcetaminophen 325 mg\nDextromethorphan HBr 10 mg\nDoxylamine succinate 6.25 mg\nPhenylephrine HCL 5 mg\nPurpose\nPain reliever\/fever reducer\nCough suppressant\nAntihistamine\nNasal decongestant\nUses\ntemporarily relieves common cold\/flu symptoms:\n• nasal congestion \n• sinus congestion & pressure \n• cough due to minor throat & bronchial irritation\n• cough to help you sleep \n• minor aches & pains \n• headache\n• fever \n• sore throat \n• runny nose & sneezing\n• reduces swelling of nasal passages\n• temporarily restores freer breathing through the nose\n• promotes nasal and\/or sinus drainage\nWarnings\nLiver warning:\n This product contains acetaminophen. Severe liver damage may occur if you take\n• more than 8 caplets in 24 hours, which is the maximum daily amount for this product\n• with other drugs containing acetaminophen • 3 or more alcoholic drinks every day while using this\nproduct\nAllergy Alert:\n acetaminophen may cause severe skin reactions. Symptoms may include: • Skin reddening\n• Blisters • Rash\nIf a skin reaction occurs, stop ues and seek medical help right away\nSore throat warning:\n If sore throat is severe, persists for more than 2 days, is accompanied or","conversation_history":[],"metadata":{"question_type":"complex","seed_document_id":29,"topic":"Lice Treatment"}}
{"id":"b4e073b9-3e4e-4d9c-8364-e7a673c48ed2","question":"What is the specific date when Walgreen Company began its marketing activities according to the provided document?","reference_answer":"The marketing start date for Walgreen Company was 05\/06\/2020.","reference_context":"Document 28: Walgreen Company\nMarketing Information\nMarketing\nCategory\nApplication Number or Monograph\nCitation\nMarketing Start\nDate\nMarketing End\nDate\nANDA\nANDA210720\n05\/06\/2020\nLabeler - \nWalgreen Company \n(008965063)\n \nRevised: 1\/2022","conversation_history":[],"metadata":{"question_type":"complex","seed_document_id":28,"topic":"Lice Treatment"}}
{"id":"19556aa3-dac9-4c37-8371-7c7da03d3d8f","question":"What are the specific medical conditions and circumstances that would prevent someone from taking chlordiazepoxide hydrochloride and clidinium bromide capsules?","reference_answer":"You should not take chlordiazepoxide hydrochloride and clidinium bromide capsules if you have glaucoma, an enlarged prostate, a bladder blockage causing urination problems, or if you are allergic to chlordiazepoxide or clidinium bromide.","reference_context":"Document 15: clidinium bromide capsules may harm others. Tell your healthcare provider if you have\nabused or been dependent on alcohol, prescription medicines or street drugs. \n• It is not known if chlordiazepoxide hydrochloride and clidinium bromide capsule is safe\nand effective in children. \n \nDo not take chlordiazepoxide hydrochloride and clidinium bromide capsules if\nyou: \n• have glaucoma \n• have an enlarged prostate \n• have a blockage of your bladder that causes problems with urination \n• are allergic to chlordiazepoxide hydrochloride or clidinium bromide\nBefore you take chlordiazepoxide hydrochloride and clidinium bromide\ncapsules, tell your healthcare provider about all of your medical conditions,\nincluding if you: \n• have eye problems \n• have problems urinating or emptying your bladder \n• have coordination problems \n• have kidney or liver problems \n• have a history of depression, mental illness, or suicidal thoughts \n• have a history of drug or alcohol abuse or addiction \n• have bleeding problems \n• are pregnant or plan to become pregnant. Chlordiazepoxide hydrochloride and\nclidinium bromide capsules may harm your unborn baby. \n     o   Taking chlordiazepoxide hydrochloride and clidinium bromide capsules late in\npregnancy may cause your baby to have symptoms of sedation (breathing problems,\nsluggishness, low muscle tone), and\/or withdrawal symptoms (jitteriness, irritability,\nrestlessness, shaking, excessive crying, feeding problems). \n    o   Tell your healthcare provider right away if you become pregnant or think you are\npregnant during treatment with chlordiazepoxide hydrochloride and clidinium bromide\ncapsules. \n• are breastfeeding or plan to breastfeed. Chlordiazepoxide hydrochloride and clidinium\nbromide may pass through your breast milk and may cause sedation, poor feeding or\npoor weight gain in your baby. Talk to your healthcare provider about the best way to\nfeed your baby if you take chlordiazepoxide hydrochloride and clidinium bromide\ncapsules. Chlordiazepoxide hydrochloride and clidinium bromide capsules may decrease\nthe amount of breast milk your body makes. \nTell your healthcare provider about all the medicines you take,\n including\nprescription and over-the-counter medicines, vitamins, and herbal supplements. \nTaking chlordiazepoxide hydrochloride and clidinium bromide capsules with certain other\nmedicines can cause side effects or affect how well chlordiazepoxide hydrochloride and\nclidinium bromide capsules or the other medicines work. Do not start or stop other\nmedicines without talking to your healthcare provider. \nEspecially tell your healthcare provider if you: \n• take a monoamine oxidase inhibitor (MAOI) medicine or an anti-psychotic medicine\ncalled phenothiazine.\nHow should I take chlordiazepoxide hydrochloride and clidinium bromide\ncapsules? \n• Take chlordiazepoxide hydrochloride and clidinium bromide capsules exactly as your\nhealthcare provider tells you to take it. \n• Your healthcare provider may change your dose of chlordiazepoxide hydrochloride\nand clidinium bromide capsules if needed. Do not change your dose of chlordiazepoxide","conversation_history":[],"metadata":{"question_type":"complex","seed_document_id":15,"topic":"Pregnancy and Medication"}}
{"id":"51e8ce81-816c-43be-83d6-23f3693dca20","question":"What are the potential signs and symptoms associated with an anticholinergic overdosage, both in terms of peripheral and central effects, and how do benzodiazepines play a role in the treatment of such toxicity?","reference_answer":"Signs and symptoms of anticholinergic overdosage may include dry mucous membranes and skin, flushing, tachycardia, hypertension, ileus, urinary retention, mydriasis, garbled speech, agitation, delirium, seizures, and hyperthermia.","reference_context":"Document 11: seizures and suicidality.\nProtracted Withdrawal Syndrome\nProtracted withdrawal syndrome associated with benzodiazepines is characterized by\nanxiety, cognitive impairment, depression, insomnia, formication, motor symptoms (e.g.,\nweakness, tremor, muscle twitches), paresthesia, and tinnitus that persists beyond 4 to\n6 weeks after initial benzodiazepine withdrawal. Protracted withdrawal symptoms may\nlast weeks to more than 12 months. As a result, there may be difficulty in differentiating\nwithdrawal symptoms from potential re-emergence or continuation of symptoms for\nwhich the benzodiazepine was being used.\nTolerance\nTolerance to chlordiazepoxide hydrochloride and clidinium bromide capsules may\ndevelop from continued therapy. Tolerance is a physiological state characterized by a\nreduced response to a drug after repeated administration (i.e., a higher dose of a drug\nis required to produce the same effect that was once obtained at a lower dose).\nTolerance to the therapeutic effects of chlordiazepoxide hydrochloride and clidinium\nbromide capsules may develop; however, little tolerance develops to the amnestic\nreactions and other cognitive impairments caused by benzodiazepines.\nOVERDOSAGE\nOverdosage of chlordiazepoxide hydrochloride and clidinium bromide capsules, which\ncontains a benzodiazepine (chlordiazepoxide hydrochloride) and an anticholinergic\n(clidinium bromide) may manifest signs and symptoms related to either of its\ncomponents, although some effects such as altered levels of consciousness may be\nsynergistic.\nOverdosage of benzodiazepines, such as chlordiazepoxide hydrochloride, is\ncharacterized by central nervous system depression ranging from drowsiness to coma.\nIn mild to moderate cases, symptoms can include drowsiness, confusion, dysarthria,\nlethargy, hypnotic state, diminished reflexes, ataxia, and hypotonia. Rarely, paradoxical\nor disinhibitory reactions (including agitation, irritability, impulsivity, violent behavior,\nconfusion, restlessness, excitement, and talkativeness) may occur. In severe\noverdosage cases, patients may develop respiratory depression and coma.\nSigns and symptoms of anticholinergic overdosage are related to excessive anti-\nmuscarinic anticholinergic activity. Peripheral signs and symptoms may include dry\nmucous membranes and skin, flushing, tachycardia, hypertension, ileus, urinary\nretention, and mydriasis. Garbled speech is often pathognomonic. Central signs and\nsymptoms may include agitation and delirium, seizures, and hyperthermia.\nBenzodiazepines are considered a first-line treatment for anticholinergic toxicity acting\nto treat mild to moderate agitation and prevent seizures.\nOverdosage of benzodiazepines in combination with other CNS depressants (including\nalcohol and opioids) may be fatal (\nsee WARNINGS, Dependence and Withdrawal\nReactions\n). Markedly abnormal (lowered or elevated) blood pressure, heart rate, or\nrespiratory rate raise the concern that additional drugs and\/or alcohol are involved in the","conversation_history":[],"metadata":{"question_type":"complex","seed_document_id":11,"topic":"Pregnancy and Medication"}}
{"id":"c00e709a-f02c-4b9f-bf6f-f34edc239f97","question":"What are the important considerations that patients should be made aware of regarding the use of chlordiazepoxide hydrochloride and clidinium bromide capsules, particularly in terms of potential abuse, withdrawal reactions, and concomitant use with other medications?","reference_answer":"Patients should be informed about the risks of abuse, misuse, and addiction associated with the use of chlordiazepoxide hydrochloride and clidinium bromide capsules. They should also be aware of the signs and symptoms of benzodiazepine abuse, misuse, and addiction, and be advised to seek medical help if they experience these. Additionally, patients should be informed about the potential withdrawal reactions that may occur upon discontinuation or rapid dosage reduction of the capsules.","reference_context":"Document 5: as the MAO inhibitors and phenothiazines are to be used. The usual precautions in\ntreating patients with impaired renal or hepatic function should be observed.\nParadoxical reactions to chlordiazepoxide hydrochloride, e.g., excitement, stimulation\nand acute rage, have been reported in psychiatric patients and should be watched for\nduring chlordiazepoxide hydrochloride and clidinium bromide capsules therapy. The\nusual precautions are indicated when chlordiazepoxide hydrochloride is used in the\ntreatment of anxiety states where there is any evidence of impending depression; it\nshould be borne in mind that suicidal tendencies may be present and protective\nmeasures may be necessary.\nInformation for Patients\nAbuse, Misuse, and Addiction\nInform patients that the use of chlordiazepoxide hydrochloride and clidinium bromide\ncapsules, even at recommended dosages, exposes users to risks of abuse, misuse, and\naddiction, which can lead to overdose and death, especially when used in combination\nwith other medications (e.g., opioid analgesics), alcohol, and\/or illicit substances\n. \nInform\npatients about the signs and symptoms of benzodiazepine abuse, misuse, and\naddiction; to seek medical help if they develop these signs and\/or symptoms; and on the\nproper disposal of unused drug (see \nWARNINGS\n)\n.\nWithdrawal Reactions\nInform patients that the continued use of chlordiazepoxide hydrochloride and clidinium\nbromide capsules may lead to clinically significant physical dependence and that abrupt\ndiscontinuation or rapid dosage reduction of chlordiazepoxide hydrochloride and\nclidinium bromide capsules may precipitate acute withdrawal reactions, which can be life-\nthreatening. Inform patients that in some cases, patients taking benzodiazepines have\ndeveloped a protracted withdrawal syndrome with withdrawal symptoms lasting weeks\nto more than 12 months. Instruct patients that discontinuation or dosage reduction of\nchlordiazepoxide hydrochloride and clidinium bromide capsules may require a slow taper\n(see \nWARNINGS \nand \nDRUG ABUSE AND DEPENDENCE\n)\n.\n \nConcomitant Use With Opioids and Other CNS Depressants\n \n \nInform patients and caregivers that potentially fatal additive effects may occur if\nchlordiazepoxide hydrochloride and clidinium bromide capsules are used with opioids or\nother CNS depressants, including alcohol, and not to use these concomitantly unless\nsupervised by a health care provider (see \nWARNINGS and PRECAUTIONS, Drug\nInteractions\n).\nPregnancy\nAdvise pregnant females that use of chlordiazepoxide hydrochloride and clidinium\nbromide capsules late in pregnancy can result in sedation (respiratory depression,\nlethargy, hypotonia) and \/or withdrawal symptoms (hyperreflexia, irritability,\nrestlessness, tremors, inconsolable crying, and feeding difficulties) in newborns (see\nWARNINGS, Neonatal Sedation and Withdrawal Syndrome and PRECAUTIONS,","conversation_history":[],"metadata":{"question_type":"complex","seed_document_id":5,"topic":"Pregnancy and Medication"}}
{"id":"a1052a5c-3071-43f3-81c6-143fc09d6d33","question":"What are the potential side effects that individuals may experience when taking chlordiazepoxide hydrochloride and clidinium bromide capsules, besides the common ones mentioned in the document?","reference_answer":"The most common side effects of chlordiazepoxide hydrochloride and clidinium bromide capsules include dry mouth, nausea, skin problems, blurred vision, constipation, swelling, irregular menstrual cycles, changes in libido, problems with urination, drowsiness, coordination problems, and confusion, especially in elderly or weak individuals.","reference_context":"Document 16: hydrochloride and clidinium bromide capsules or suddenly stop taking chlordiazepoxide\nhydrochloride and clidinium bromide capsules without talking with your healthcare\nprovider. \n• If you take too much chlordiazepoxide hydrochloride and clidinium bromide capsules,\ncall your healthcare provider or go to the nearest hospital emergency room right away. \nWhat are the possible side effects of chlordiazepoxide hydrochloride and\nclidinium bromide capsules? \nChlordiazepoxide hydrochloride and clidinium bromide capsules may cause\nserious side effects, including: See “What is the most important information\nI should know about chlordiazepoxide hydrochloride and clidinium bromide\ncapsules?” \n• Chlordiazepoxide hydrochloride and clidinium bromide capsules can make\nyou sleepy or dizzy and can slow your thinking and motor skills.\n \n        o Do not drive, operate heavy machinery, or do other dangerous activities until you\nknow how chlordiazepoxide hydrochloride and clidinium bromide capsule affects you. \n      o Do not drink alcohol or take other drugs that may make you sleepy or dizzy while\ntaking chlordiazepoxide hydrochloride and clidinium bromide capsules without first\ntalking to your healthcare provider. When taken with alcohol or drugs that cause\nsleepiness or dizziness, chlordiazepoxide hydrochloride and clidinium bromide capsules\nmay make your sleepiness or dizziness much worse. \nThe most common side effects of chlordiazepoxide hydrochloride and\nclidinium bromide capsules include: \n• dry mouth                     • nausea                • skin problems\n• blurred vision               • constipation        • swelling\n• irregular menstrual (periods) cycles\n• increase and decreased desire for sex\n   (libido)\n• problems starting to urinate\n• drowsiness, coordination problems, and \n  confusion may happen, especially in people \n  who are elderly or weak\nThese are not all the possible side effects of chlordiazepoxide hydrochloride and\nclidinium bromide capsules. \nCall your doctor for medical advice about side effects. You may report side effects to\nFDA at 1-800-FDA-1088. \nHow should I store chlordiazepoxide hydrochloride and clidinium bromide\ncapsules? \n• Store chlordiazepoxide hydrochloride and clidinium bromide capsules at room\ntemperature 77°F (25°C). \n• Bottles of 100’s count are child-resistant.\n•\n \nKeep chlordiazepoxide hydrochloride and clidinium bromide capsules and all\nmedicines out of the reach of children. \nGeneral information about the safe and effective use of chlordiazepoxide\nhydrochloride and clidinium bromide capsules.\n \nMedicines are sometimes prescribed for purposes other than those listed in a Medication\nGuide. Do not take chlordiazepoxide hydrochloride and clidinium bromide capsules for a\ncondition for which it was not prescribed. Do not give chlordiazepoxide hydrochloride\nand clidinium bromide capsules to other people, even if they have the same symptoms\nthat you have. It may harm them. You can ask your pharmacist or healthcare provider\nfor information about chlordiazepoxide hydrochloride and clidinium bromide capsules","conversation_history":[],"metadata":{"question_type":"complex","seed_document_id":16,"topic":"Pregnancy and Medication"}}
{"id":"10941078-7706-41f9-926d-4f485db298ff","question":"What are some of the adverse reactions that have been reported during therapy with chlordiazepoxide hydrochloride and clidinium bromide capsules, including specific symptoms like dryness of the mouth, blurring of vision, urinary hesitancy, and constipation?","reference_answer":"Some adverse reactions reported during therapy with chlordiazepoxide hydrochloride and clidinium bromide capsules include skin eruptions, edema, minor menstrual irregularities, nausea, constipation, extrapyramidal symptoms, changes in EEG patterns, blood dyscrasias such as agranulocytosis, jaundice, hepatic dysfunction, dryness of the mouth, blurring of vision, urinary hesitancy, and constipation.","reference_context":"Document 9: instances syncope has been reported.\nOther adverse reactions reported during therapy with chlordiazepoxide hydrochloride\ninclude isolated instances of skin eruptions, edema, minor menstrual irregularities,\nnausea and constipation, extrapyramidal symptoms, as well as increased and decreased\nlibido. Such side effects have been infrequent and are generally controlled with reduction\nof dosage. Changes in EEG patterns (low-voltage fast activity) have been observed in\npatients during and after chlordiazepoxide hydrochloride treatment.\nBlood dyscrasias, including agranulocytosis, jaundice and hepatic dysfunction have\noccasionally been reported during therapy with chlordiazepoxide hydrochloride. When\nchlordiazepoxide hydrochloride treatment is protracted, periodic blood counts and liver\nfunction tests are advisable.\nAdverse effects reported with use of chlordiazepoxide hydrochloride and clidinium\nbromide capsules are those typical of anticholinergic agents, i.e., dryness of the mouth,\nblurring of vision, urinary hesitancy and constipation. Constipation has occurred most\noften when chlordiazepoxide hydrochloride and clidinium bromide therapy has been\ncombined with other spasmolytic agents and\/or a low residue diet.\nTo report SUSPECTED ADVERSE REACTIONS, contact \nAlembic Pharmaceuticals\nLimited at 1-866-210-9797\n or FDA at 1-800-FDA-1088 or\nwww.fda.gov\/medwatch.\nDRUG ABUSE AND DEPENDENCE\nControlled Substance\nChlordiazepoxide hydrochloride and clidinium bromide capsules contain chlordiazepoxide\nhydrochloride, a Schedule IV controlled substance and clidinium bromide, which is not a\ncontrolled substance. Chlordiazepoxide hydrochloride and clidinium bromide capsule is\nexempted from Schedule IV and is not controlled under the Controlled Substances Act.\nAbuse\nChlordiazepoxide hydrochloride, a component of chlordiazepoxide hydrochloride and\nclidinium bromide, is a CNS depressant with a potential for abuse and addiction. Abuse is\nthe intentional, non-therapeutic use of a drug, even once, for its desirable psychological\nor physiological effects. Misuse is the intentional use, for therapeutic purposes, of a\ndrug by an individual in a way other than prescribed by a health care provider or for\nwhom it was not prescribed. Drug addiction is a cluster of behavioral, cognitive, and\nphysiological phenomena that may include a strong desire to take the drug, difficulties in\ncontrolling drug use (e.g., continuing drug use despite harmful consequences, giving a\nhigher priority to drug use than other activities and obligations), and possible tolerance\nor physical dependence. Even taking benzodiazepines as prescribed may put patients at\nrisk for abuse and misuse of their medication. Abuse and misuse of benzodiazepines\nmay lead to addiction.","conversation_history":[],"metadata":{"question_type":"complex","seed_document_id":9,"topic":"Others"}}
{"id":"b1d2aed4-6356-4c69-bf68-691cfa5a3f8b","question":"What actions should patients take if they are pregnant or breastfeeding while using chlordiazepoxide hydrochloride and clidinium bromide capsules, considering the potential risks and effects on neonates?","reference_answer":"Patients should inform their healthcare provider if they are pregnant or breastfeeding while taking chlordiazepoxide hydrochloride and clidinium bromide capsules.","reference_context":"Document 6: Pregnancy\n). Instruct patients to inform their healthcare provider if they are pregnant.\nNursing\nInstruct patients to notify their healthcare provider if they are breastfeeding or intend to\nbreastfeed (see \nPRECAUTIONS, Nursing Mothers\n).\nDrug Interactions\nOpioids\n \nThe concomitant use of benzodiazepines, including chlordiazepoxide hydrochloride, a\ncomponent of chlordiazepoxide hydrochloride and clidinium bromide capsules and\nopioids increases the risk of respiratory depression because of actions at different\nreceptor sites in the CNS that control respiration. Benzodiazepines interact at GABA\nsites and opioids interact primarily at mu receptors. When benzodiazepines and opioids\nare combined, the potential for benzodiazepines to significantly worsen opioid-related\nrespiratory depression exists. Limit dosage and duration of concomitant use of\nchlordiazepoxide hydrochloride and clidinium bromide capsules and opioids, and follow\npatients closely for respiratory depression and sedation.\nOral Anticoagulants\nAlthough clinical studies have not established a cause and effect relationship, physicians\nshould be aware that variable effects on blood coagulation have been reported very\nrarely in patients receiving oral anticoagulants and chlordiazepoxide hydrochloride, a\ncomponent of chlordiazepoxide hydrochloride and clidinium bromide capsules.\nPregnancy\nRisk Summary\nChlordiazepoxide Hydrochloride\nNeonates born to mothers using benzodiazepines during the later stages of pregnancy\nhave been reported to experience symptoms of sedation and\/or neonatal withdrawal\n(see \nWARNINGS, Neonatal Sedation and Withdrawal Syndrome \nand\nPRECAUTIONS: \nClinical Considerations). Available data from published observational\nstudies of pregnant women exposed to benzodiazepines do not report a clear\nassociation with benzodiazepines and major birth defects \n(see Data).\nClidinium Bromide\nOver decades of use, there is an absence of published data on orally administered\nclidinium bromide in pregnant women, including an absence of any reports of a drug-\nassociated risk of major birth defects, miscarriage, or other adverse maternal or fetal\noutcomes.\nThe background risk of major birth defects and miscarriage for the indicated population\nis unknown. All pregnancies have a background risk of birth defect, loss, or other\nadverse outcomes. In the U.S. general population, the estimated risk of major birth\nA","conversation_history":[],"metadata":{"question_type":"complex","seed_document_id":6,"topic":"Pregnancy and Medication"}}
{"id":"8e290c0a-9a22-4228-a60e-85a8add3f2c6","question":"When did the marketing of the product from Savings Distributors LLC begin according to the provided document?","reference_answer":"The marketing start date for the product from Savings Distributors LLC is 07\/08\/2019.","reference_context":"Document 33: Savings Distributors LLC\n3\nNDC:73097-009-20\n40 \nin 1 CARTON\n07\/08\/2019\n3\n2 \nin 1 POUCH; Type 0: Not a Combination Product\nMarketing Information\nMarketing Category\nApplication Number or Monograph Citation\nMarketing Start Date\nMarketing End Date\nOTC monograph final\npart341\n07\/08\/2019\nLabeler - \nSavings Distributors LLC \n(010527359)\n \nRevised: 7\/2019","conversation_history":[],"metadata":{"question_type":"complex","seed_document_id":33,"topic":"Lice Treatment"}}
{"id":"47d465d0-26e7-4dd3-b2c3-3a16844c2cba","question":"What are the names and strengths of the active ingredients present in the chlordiazepoxide hydrochloride and clidinium bromide capsule?","reference_answer":"The active ingredients in the chlordiazepoxide hydrochloride and clidinium bromide capsule are Chlordiazepoxide Hydrochloride with a strength of 5 mg and Clidinium Bromide with a strength of 2.5 mg.","reference_context":"Document 18: CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE  \nchlordiazepoxide hydrochloride and clidinium bromide capsule\nProduct Information\nProduct Type\nHUMAN PRESCRIPTION DRUG\nItem Code (Source)\nNDC:62332-744\nRoute of Administration\nORAL\nDEA Schedule\nCIV    \nActive Ingredient\/Active Moiety\nIngredient Name\nBasis of Strength\nStrength\nCHLORDIAZEPOXIDE HYDROCHLORIDE\n (UNII: MFM6K1XWDK)\n(CHLORDIAZEPOXIDE - UNII:6RZ6XEZ3CR)\nCHLORDIAZEPOXIDE\nHYDROCHLORIDE\n5 mg\nCLIDINIUM BROMIDE\n (UNII: 91ZQW5JF1Z) \n(CLIDINIUM - UNII:BO76JF850N)\nCLIDINIUM BROMIDE\n2.5 mg\nInactive Ingredients\nIngredient Name\nStrength\nLACTOSE MONOHYDRATE\n (UNII: EWQ57Q8I5X)\n \nSTARCH, CORN\n (UNII: O8232NY3SJ)\n \nTALC\n (UNII: 7SEV7J4R1U)\n \nTITANIUM DIOXIDE\n (UNII: 15FIX9V2JP)\n \nFD&C GREEN NO. 3\n (UNII: 3P3ONR6O1S)\n \nD&C YELLOW NO. 10\n (UNII: 35SW5USQ3G)\n \nGELATIN, UNSPECIFIED\n (UNII: 2G86QN327L)\n \nSHELLAC\n (UNII: 46N107B71O)\n \nFERROSOFERRIC OXIDE\n (UNII: XM0M87F357)","conversation_history":[],"metadata":{"question_type":"complex","seed_document_id":18,"topic":"Pregnancy and Medication"}}
